If true, selective activators of the peripherally accessible orexigenic TrkB site would represent novel therapeutic agents for anorexia and cachexia while selective inhibitors of this system may find utility in the treatment for hyperphagia and obesity. The gene discussed is NTRK2; the disease is obesity disorder.